Nivolumab

Generic Name
Nivolumab
Brand Names
Opdivo, Opdualag
Drug Type
Biotech
Chemical Formula
-
CAS Number
946414-94-4
Unique Ingredient Identifier
31YO63LBSN
Background

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...

Indication

Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...

Associated Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
Complete Surgical Resection, Neoadjuvant Therapies
Clinical Trials
Related News

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

First Posted Date
2023-09-08
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
156
Registration Number
NCT06029270
Locations
🇺🇸

Oncology Associates PC, Omaha, Nebraska, United States

🇺🇸

Kaiser Permanente Dublin, Dublin, California, United States

🇺🇸

Kaiser Permanente-Fremont, Fremont, California, United States

and more 61 locations

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

First Posted Date
2023-08-31
Last Posted Date
2024-05-16
Lead Sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Target Recruit Count
57
Registration Number
NCT06019130
Locations
🇩🇪

Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany

🇩🇪

Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany

🇩🇪

Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany

and more 28 locations

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

First Posted Date
2023-08-29
Last Posted Date
2024-02-05
Lead Sponsor
Georgetown University
Target Recruit Count
54
Registration Number
NCT06015724
Locations
🇺🇸

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Induction Chemo-Nivo in Unresectable Stage III NSCLC

First Posted Date
2023-08-21
Last Posted Date
2023-11-07
Lead Sponsor
Ralph G Zinner
Target Recruit Count
37
Registration Number
NCT06003075
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

First Posted Date
2023-08-14
Last Posted Date
2024-12-09
Lead Sponsor
IDEAYA Biosciences
Target Recruit Count
420
Registration Number
NCT05987332
Locations
🇺🇸

Honor Health, Scottsdale, Arizona, United States

🇺🇸

Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

and more 63 locations

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

First Posted Date
2023-08-14
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1190
Registration Number
NCT05987241
Locations
🇺🇸

Montefiore Medical Center-Einstein Campus, Bronx, New York, United States

🇺🇸

Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

🇺🇸

University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States

and more 310 locations

Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

First Posted Date
2023-07-05
Last Posted Date
2024-05-17
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
36
Registration Number
NCT05931393
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

First Posted Date
2023-07-03
Last Posted Date
2024-10-23
Lead Sponsor
Michael B. Atkins, MD
Target Recruit Count
120
Registration Number
NCT05928806
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Yale University, Yale Cancer Center, New Haven, Connecticut, United States

and more 9 locations

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

First Posted Date
2023-07-03
Last Posted Date
2024-12-03
Lead Sponsor
Pfizer
Target Recruit Count
150
Registration Number
NCT05926960
Locations
🇮🇹

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

🇮🇹

Istituto Europeo di Oncologia IRCCS, Milano, Italy

🇸🇰

Nemocnica Poprad, a.s., Poprad, Slovakia

and more 60 locations

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

First Posted Date
2023-06-27
Last Posted Date
2024-12-17
Lead Sponsor
Servier Bio-Innovation LLC
Target Recruit Count
7
Registration Number
NCT05921760
Locations
🇺🇸

UCSF - Medical Center at Mission Bay, San Francisco, California, United States

🇺🇸

Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy